Abstract
Background Immigration is a determinant of tuberculosis (TB) epidemiology. The US-Mexican border state of Tamaulipas serves as a migration waypoint for further immigration to the US, and has the second highest incidence of TB in Mexico. Here, we determined the contribution and characteristics of immigrants to the TB burden in Tamaulipas.
Methods TB surveillance data from Tamaulipas (2006-2013) was used to conduct a cross-sectional characterization of TB immigrants (born outside Tamaulipas) and identify their association with TB treatment outcomes.
Results Immigrants comprised 30.8% of the TB patients, with >99% originating from internal Mexican migration. Most migration was from South to North, with cities adjacent to the US border as destinations. Immigrants had higher odds of risk factors for TB [older age (≥ 65 yr old, OR 2.4, 95% CI 2.1, 2.8), low education (OR 1.3, 95% CI 1.2, 1.4), diabetes (OR 1.2, 95% CI 1.1, 1.4)], or abandoning TB treatment (adjusted OR 1.2, 95% CI 1.0, 1.5).
Conclusions The US port of entry of Tamaulipas has a predominant south to north migration, positively impacting TB prevalence in this region. There is a need to identify strategies to prevent and manage TB more effectively in this Mexican migration waypoint.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive funding support from an agency, commercial or not-for-profit sectors. BIR has current funding support from NIH, NIA P01-AG051428 and NIAID 1R21AI144541
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board of the University of Texas Health Science Center at Houston (Human Subject IRB # HSC-SPH-15-0489) and the Research Committee for the Secretaria de Salud de Tamaulipas (Human Subjects IRB# 076/2015/CEI).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
Data will be provided as per request
